Ethan Dmitrovsky
22Patents
2h-index
22Co-inventors
57Inventor score
Filing activity: Jul 21, 1993 → Jul 7, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8417324B2 | Fluorescence lifetime spectrometer (FLS) and methods of detecting diseased tissue | Physics | 16 | Active |
| US5843642A | Methods for detection of acute promyelocytic leukemia (APL) | Emerging Cross-Sectional Technologies | 3 | Expired |
| US10201512B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 2 | Active |
| US7955848B2 | MicroRNA biomarkers for human breast and lung cancer | Chemistry; Metallurgy | 2 | Active |
| US11166927B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 1 | Active |
| US8283113B2 | Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG15 and/or UBP43 | Chemistry; Metallurgy | 1 | Active |
| US8068898B2 | Fluorescence lifetime spectrometer (FLS) and methods of detecting diseased tissues | Physics | 1 | Expired |
| US10034845B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 1 | Active |
| US10285960B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US11246845B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US9056135B2 | MicroRNA biomarkers for human breast and lung cancer | Chemistry; Metallurgy | 0 | Active |
| US8124371B2 | Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation | Physics | 0 | Active |
| US8207325B2 | MicroRNA biomarkers for human breast and lung cancer | Chemistry; Metallurgy | 0 | Active |
| US10945976B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US10695307B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US11547684B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US10653650B2 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists | Human Necessities | 0 | Active |
| US11576881B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US7586022B2 | Transgenic non-human animal model of lung tumorigenesis | Chemistry; Metallurgy | 0 | Active |
| US12383521B2 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists | Human Necessities | 0 | Active |
| US11793781B2 | Autoimmune disorder treatment using RXR agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US8697668B2 | Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG215 and/or UBP43 | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.